Role of GPCR Signaling in Anthracycline-Induced Cardiotoxicity
Cells · 22.01.2025 · 14 (3) · 169
DOI: 10.3390/cells14030169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 22.01.2025. Verfasst von Nimish Biswal und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Xavier University at Aruba, Oranjestad, Aruba. Hauptthemen laut MEDLINE: Cardiotoxicity, Anthracyclines, Signal Transduction, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 258 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: W.W. Smith Charitable Trust Fund, Sharpe-Strumia Research Foundation, NCI NIH HHS.
Abstract (Originalsprache)
Anthracyclines are a class of chemotherapeutics commonly used to treat a range of cancers. Despite success in improving cancer survival rates, anthracyclines have dose-limiting cardiotoxicity that prevents more widespread clinical utility. Currently, the therapeutic options for these patients are limited to the iron-chelating agent dexrazoxane, the only FDA-approved drug for anthracycline cardiotoxicity. However, the clinical use of dexrazoxane has failed to replicate expectations from preclinical studies. A limited list of GPCRs have been identified as pathogenic in anthracycline-induced cardiotoxicity, including receptors (frizzled, adrenoreceptors, angiotensin II receptors) previously implicated in cardiac remodeling in other pathologies. The RNA sequencing of iPSC-derived cardiac myocytes from patients has increased our understanding of the pathogenic mechanisms driving cardiotoxicity. These data identified changes in the expression of novel GPCRs, heterotrimeric G proteins, and the regulatory pathways that govern downstream signaling. This review will capitalize on insights from these experiments to explain aspects of disease pathogenesis and cardiac remodeling. These data provide a cornucopia of possible unexplored potential pathways by which we can reduce the cardiotoxic side effects, without compromising the anti-cancer effects, of doxorubicin and provide new therapeutic options to improve the recovery and quality of life for patients undergoing chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Xavier University at Aruba, Oranjestad, Aruba.
- Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Wynnewood, PA 19096, USA.
- The Wistar Institute, Philadelphia, PA 19104, USA.
- Division of Perinatal Research, Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW 2065, Australia.
- Division of Cardiovascular Medicine, Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA.
ORCID-Profile: Richard G Pestell, Anthony W Ashton
Förderung
- W.W. Smith Charitable Trust Fund
- Sharpe-Strumia Research Foundation
- NCI NIH HHS
- Heart Research Australia
- NHLBI NIH HHS
- Bushell Foundation
- NIH HHS
- NIH
Zitieren
APA
Biswal, N., Harish, R., Roshan, M., Samudrala, S., Jiao, X., Pestell, R. G., & Ashton, A. W. (2025). Role of GPCR Signaling in Anthracycline-Induced Cardiotoxicity. Cells, 14(3), 169. https://doi.org/10.3390/cells14030169
Vancouver
Biswal N, Harish R, Roshan M, Samudrala S, Jiao X, Pestell RG, et al. Role of GPCR Signaling in Anthracycline-Induced Cardiotoxicity. Cells. 2025;14(3):169. doi:10.3390/cells14030169
BibTeX
@article{Biswal2025,
author = {Biswal, Nimish and Harish, Ritika and Roshan, Minahil and Samudrala, Sathvik and Jiao, Xuanmao and Pestell, Richard G and Ashton, Anthony W},
title = {Role of GPCR Signaling in Anthracycline-Induced Cardiotoxicity},
journal = {Cells},
year = {2025},
volume = {14},
number = {3},
pages = {169},
doi = {10.3390/cells14030169}
}
EUVIMED